|
J Biol Chem, Vol. 274, Issue 29, 20550-20560, July 16, 1999
Intact LIM 3 and LIM 4 Domains of Paxillin Are Required for
the Association to a Novel Polyproline Region (Pro 2) of
Protein-Tyrosine Phosphatase-PEST*
Jean-François
Côté §,
Christopher E.
Turner¶ , and
Michel L.
Tremblay **
From the Department of Biochemistry, McGill
University, Montréal, Québec H3G 1Y6, Canada and the
¶ Department of Anatomy and Cell Biology, Program in Cell and
Molecular Biology, State University of New York Health Science Center,
Syracuse, New York 13210
 |
ABSTRACT |
The focal adhesion protein
p130Cas was identified as a substrate for the
protein-tyrosine phosphatase (PTP)-PEST, and the specificity of
this interaction is mediated by a dual mechanism involving a Src
homology 3 domain-mediated binding and PTP domain recognition. Recently, paxillin was also demonstrated to interact with PTP-PEST (Shen, Y., Schneider, G., Cloutier, J. F., Veillette, A., and Schaller, M. D. (1998) J. Biol. Chem. 273, 6474-6481). In the present study, we show that amino acids 344-397 of
PTP-PEST are sufficient for the binding to paxillin. We demonstrate
that a proline-rich segment of PTP-PEST (Pro 2),
355PPEPHPVPPILTPSPPSAFP374, is essential for
this interaction in vivo. Furthermore, mutation of proline
residues within the Pro 2 motif reveal that proline 362 is critical for
the binding of paxillin. Conversely, using deletion and point mutants
of paxillin, LIM 3 and 4 domains were both found to be necessary for
binding of PTP-PEST. Finally, using a "substrate trapping"
approach, we demonstrate that, unlike p130Cas, paxillin is
not a substrate for PTP-PEST. In conclusion, we show that a novel
proline-rich motif found in PTP-PEST serves as a ligand for the LIM
domains of paxillin. Interestingly, the focal adhesion targeting of
paxillin is mediated by LIM 3. Thus, we propose that PTP-PEST, by a
competition with the ligand of paxillin in the focal adhesion complex,
could contribute to the removal of paxillin from the adhesion sites and
consequently promote focal adhesion turnover.
 |
INTRODUCTION |
Protein-tyrosine kinases are involved in the propagation of
extracellular signals from a number of trans-membrane receptors. Although some receptors like the epidermal growth factor and
platelet-derived growth factor receptors have intrinsic tyrosine kinase
activities. Others such as the integrin and T cell receptor must couple
intracellular tyrosine kinases to propagate their signals. In both
scenarios, protein-tyrosine phosphatases
(PTPs)1 have also been shown
to play key roles in regulating, in a positive or negative manner,
these signaling cascades (1, 2).
PTP-PEST is ubiquitously expressed throughout murine development as
well as in the adult animal (3). The enzyme is composed of a N-terminal
catalytic domain and a C-terminal tail rich in proline stretches that
serve as binding sites for other signaling molecules. PTP-PEST has been
proposed to influence mitogenic signaling downstream of the epidermal
growth factor receptor due to its direct association with two key
adaptor proteins, Shc and Grb2 (4-6). More recently, using substrate
trapping approaches (7), the adaptor protein p130Cas was
identified as a substrate of PTP-PEST (8). The SH3 domain of
p130Cas as well as those of the related proteins Hef1 and
Sin/Efs were shown to directly bind to the Pro 1 of PTP-PEST (9, 10). This interaction thus serves as an additional mechanism to confer specificity to PTP-PEST toward its substrates. p130Cas is a
focal adhesion-localized protein whose tyrosine phosphorylation is
mainly regulated by integrin engagement via the catalytic activity of
p125FAK and c-Src (11). Focal adhesions are the sites of
cell contact with the extracellular matrix (for review, see Refs. 12
and 13). Proteins found in focal adhesions have either structural or
signaling functions. Through the juxtaposition of several enzymes and
adaptor proteins such as p125FAK, p130Cas, and
Src, the extracellular matrix can connect with the actin-cytoskeleton (12). Studies on PTP-PEST / fibroblasts have demonstrated impaired
cell migration (14). This is related to the hyperphosphorylation of
three focal adhesion-localized proteins, namely p130Cas,
p125FAK, and paxillin in the / cells. In addition, a
higher number of vinculin-containing focal adhesions were observed in
the / fibroblast, in agreement with increase phosphorylation on
tyrosine of the focal adhesion proteins mentioned above. These results indicate a role for PTP-PEST in focal adhesion breakdown and turnover, which are required in events such as cell migration (15). Consistent with these results, it has recently been demonstrated that Rat-1 fibroblasts overexpressing WT PTP-PEST are not efficient for migration in a wound healing assay due to p130Cas hypophosphorylation
(16).
Paxillin is a member of a family of adaptor proteins that also includes
Hic-5 (17) and leupaxin (18). Located in focal adhesions, paxillin
associates with important cytoskeletal proteins such as talin and
vinculin as well as protein-tyrosine kinases found in adhesion plaques
such as p125FAK, Pyk2, and c-Src (19). In particular, the
association of p125FAK with paxillin has been shown to be
essential for focal adhesion targeting of p125FAK (20). In
addition, following integrin engagement, paxillin has been demonstrated
to be phosphorylated by p125FAK and c-Src (21, 22). This
creates docking sites for the SH2 domain of the Crk proteins (23) and
links the integrin activation to signal transduction pathways via
the proteins C3G or SOS that are bound to Crk. In addition to its
tyrosine phosphorylation, paxillin is also heavily phosphorylated on
serine and threonine residues following plating of cells on fibronectin
(24). Serine and threonine phosphorylation of paxillin have been
implicated in its targeting to focal adhesions and cellular attachment
to fibronectin (25).
Structurally, paxillin and the paxillin-like proteins are composed of
N-terminal LD motifs and four C-terminal LIM domains. The LD motifs of
paxillin (reviewed in Ref. 26) have been shown to be implicated in the
paxillin binding to p125FAK and vinculin (19). LD motifs
have also been observed in a variety of proteins, where they also act
as mediating protein-protein interaction (26). LIM domains are
approximately 50 amino acids in length and known to mediate
protein-protein associations (for review, see Refs. 27 and 28). The LIM
domains have a conserved consensus sequence:
(CXXC(X16-23)HXXC)XX(CXXC(X16-21)CXXC/D/H) (28). Proteins harboring LIM domains often harbor other domains such as
homeodomain, kinase, SH3, and LD domains. One of the most characterized
LIM domain mediated interaction involves the association of the LIM 3 of Enigma to the tyrosine-based motif (tyrosine tight turn) of the
insulin receptor (29). Similarly, the LIM 2 of Enigma interacts with
the Ret receptor tyrosine kinase (29). These interactions indicate that
each LIM domain may indeed recognize and interact with specific protein
domains. The LIM domains of paxillin, especially LIM 3, are essential
for proper focal adhesion targeting. Although the focal adhesion
targeting ligand of LIM 3 has not been identified (19), it has recently
been shown that LIM 2 and 3 bind protein(s) with serine kinase activity
(25).
In a recent report, paxillin was shown to associate directly with
the C-terminal tail of PTP-PEST by a still uncharacterized mechanism
(30). In the present study, we reveal that a non-classical proline-rich
motif of PTP-PEST (Pro 2) is essential for both in vitro and
in vivo binding of PTP-PEST to paxillin. More precisely, mutation of proline 362 to alanine completely abolishes this
association. The presence of intact LIM 3 and 4 domains of paxillin
were required for its association with PTP-PEST. Finally, using mutants
of PTP-PEST which have a C231S mutation, we demonstrate that paxillin
is not a substrate for PTP-PEST in a substrate trapping assay.
Together, these results demonstrate a novel association between LIM
domains and a proline-rich motif. We propose that a physiological
function for this association could be that, once PTP-PEST is recruited to adhesion plaques, it could regulate the breakdown and turnover of
focal adhesions by dephosphorylating and/or binding proteins such as
paxillin, p130Cas, Shc, and Grb2.
 |
MATERIALS AND METHODS |
Cell Lines, Transient Transfections, and Pervanadate
Treatment--
NIH 3T3, NIH 3T3 overexpressing a Src Y527F
constitutively active mutant, and HEK 293T cell lines were routinely
maintained in Dulbecco's modified Eagle's medium supplemented with
10% fetal bovine serum and penicillin/streptomycin (Life Technologies,
Inc.). HEK 293T cells were transfected with 5 µg of PTP-PEST plasmid using the calcium phosphate technique as described previously (10). NIH
3T3 cells were pervanadate-treated for 30 min as described previously
(10).
Antibodies--
The monoclonal antibodies against paxillin
(P13520) and p130Cas (P27820) were from Transduction
Laboratories. The polyclonal antibody specific for avian paxillin was
described previously (19). The anti-GST and anti-HA tag antibody 12CA5
were obtained from Santa Cruz Biotechnology. The anti-phosphotyrosine
antibodies 4G10, PY20, and PY99 were from Upstate Biotechnologies,
Transduction Laboratories, and Santa Cruz Biotechnology, respectively.
The polyclonal antibody 1075 against PTP-PEST has been described
previously (3).
Plasmid Construction--
PTP-PEST cDNA in the expression
vector pACTAG (HA epitope-tagged) was described previously (3). The Pro
1 (331PPKPPR337) and Pro 2 (355PPEPHPVPPILTPSPPSAFP374) domains of
PTP-PEST were deleted by PCR. Briefly, an antisense oligonucleotide
upstream of the Pro 1 (5'-TCGCTCGAGAGAGTCTTGCTTCTC-3') designed with a
XhoI site was used to amplify the cDNA of PTP-PEST in
combination with the sense oligonucleotide T7. This PCR product, encoding for the N terminus of PTP-PEST, was gel-purified (QIAEX II,
Qiagen) and digested with NotI and XhoI. A second
PCR product encoding for the C terminus of PTP-PEST was generated using
a sense oligonucleotide with an XhoI site designed
downstream of the Pro 1 (5'-CCACTCGAGACTCGAAGTTGCCTT-3') and an
antisense oligonucleotide with a XbaI site
(5'-CCTCTAGATCATGTCCATTCTGAA-3'). The PCR product, encoding for the C
terminus of PTP-PEST, was gel-purified and digested with
XhoI and XbaI. To reconstitute the full-length
PTP-PEST with the deleted Pro 1 region, the digested PCR products
encoding for the PTP-PEST N and C terminus domains were ligated in the NotI and XbaI sites of pACTAG. The Pro 2 region
of PTP-PEST was deleted using a similar strategy. The deletions were
verified by dideoxy sequencing of the mutated region using Sequenase
(Amersham Pharmacia Biotech). Truncations of the GST PTP-PEST 344-437
(Pro 2) (GST 344-427, 344-417, 344-407, and 344-397) were performed by PCR using T7 primer and PTP-PEST specific oligonucleotides harboring
an EcoRI site. The PCR products were digested with
BamHI and EcoRI and ligated in the
BamHI and EcoRI sites of pGEX RC. GST PTP-PEST
344-385 was generated by digestion of the pGEX RC 344-437 vector with
KpnI and EcoRI, treatment with mung bean
nuclease, followed by religation of the plasmid.
The constructs encoding for the N terminus, C terminus, and LIM 1-4 of
avian paxillin fused to GST in the pGEX 2T vector have been described
previously(19). The paxillin GST LIM 1-3 was constructed by subcloning
from the GST C terminus pGEX 2T construct the
BamHI/SacII fragment in pBluescript II (KS). The
BamHI/SacI fragment was then subcloned from
pBluescript II (KS) to pGEX RC in the BamHI/SacI sites. The paxillin GST LIM 1-2 of paxillin was constructed by subcloning the BamHI/XbaI fragment from the GST C
terminus construct in pGEX RC in the BamHI/XbaI
sites. The paxillin GST LIM 3-4 was constructed by subcloning the
XmnI/EcoRI fragment from the GST C terminus of
paxillin in pGEX 2TK in the SmaI/EcoRI sites. The paxillin GST C terminus LIM 3 was constructed by digesting the paxillin GST C terminus construct with XbaI and
SacII, followed by treatment with mung bean nuclease and
religation of the plasmid.
Site-directed Mutagenesis--
Eight proline residues
(highlighted) found in the Pro 2 domain of PTP-PEST
(355PPEPHPVPPILTPSPPSAFP374)
were mutated to alanine residues by PCR. Briefly, mutagenic oligonucleotides were engineered: P358A
(5'-CAGCCACCAGAAGCTCACCCGGTGC-3'), P360A
(5'-CCAGAACCTCACGCGGTGCCACCCATC-3'), P362A
(5'-CCTCACCCGGTGGCACCCATCCTGAC-3'), P363A
(5'-CACCCGGTGCCAGCCATCCTGACGC-3'), P367A
(5'-CCCATCCTGACGGCATCACCTCCTTC-3'), P369A
(5'-CTGACGCCATCAGCTCCTTCAGCC-3'), P370A
(5'-ACGCCATCACCTGCTTCAGCCTTCC-3'), P374A
(5'-CCTTCAGCCTTCGCAACCGTTACCAC-3'). pGEX RC PTP-PEST Pro 2 (aa
344-437) was used as a templates for the PCR reactions. Each
oligonucleotide was used in combination with a pGEX antisense specific
oligonucleotide to amplify a portion of the Pro 2 region. The eight
different PCR products were gel-purified. A second PCR product was
generated using a pGEX-specific sense oligonucleotide in combination
with a PTP-PEST-specific antisense primer (5'-CCATGTGCAGCACTGGCTTT-3') and was recovered by gel purification. In order to reconstitute the
full-length Pro 2 region, each mutagenic PCR products was incubated
with the second PCR product and a strand overlap extension step was
performed with Vent DNA polymerase (New England Biolabs) for seven
cycles using the following conditions: 94 °C for 30 s, 50 °C
for 30 s, and 72 °C for 30 s. Each of the products from the strand overlap extension step was amplified by PCR by adding 100 pmol of the pGEX sense and antisense primers and using the same
conditions for 30 cycles. Each of the PCR products was gel-purified and
digested with BamHI and EcoRI and ligated in the
BamHI and EcoRI sites of pGEX RC. Following
transformation in Escherichia coli DH5 , mutants were
screened by DNA sequencing. Using a similar approach, cysteine 523 of
paxillin was mutated to a serine. The other mutants of paxillin have
been described previously(19).
In Vitro Translation--
pcDNA3 paxillin WT, LIM3,
C467A, C470A, C467/470A, LIM4, C523S, and pcDNA3 were digested
with XhoI. The linearized plasmids were used as templates
for in vitro transcription using T7 RNA polymerase (New
England Biolabs). Two µl of the transcription reactions were used to
performed in vitro translation in the presence of
[35S]methionine and rabbit reticulocyte lysate (Promega).
The in vitro translated products were tested for binding to
1 µg of GST PTP-PEST 344-397 or GST alone.
In Vitro Binding Assay Using GST Fusion Proteins--
NIH 3T3,
NIH 3T3 Src Y527F, pervanadate-treated NIH 3T3, and HEK 293T cells were
lysed in HNMETG buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1.5 mM MgCl2, 1 mM EDTA, 1% Triton X-100, and 10% glycerol) supplemented
with Complete protease inhibitors (Roche Molecular Biochemicals) and 1 mM Na3VO4 as described previously (10) The lysates were cleared of cellular debris by centrifugation at
16,000 × g in a 4 °C microcentrifuge. Protein
concentrations were determined using the Bradford method (Bio-Rad)
using bovine serum albumin as a standard. PTP-PEST,
p130Cas, and paxillin GST fusion proteins were expressed by
induction for 2 h of exponentially growing bacterial cultures with
1 mM isopropyl-1-thio- -D-galactopyranoside
and fusion proteins were extracted and immobilized on
glutathione-Sepharose beads according to the manufacturer's
recommendations. Aliquot of 200-250 µg of cell lysates, precleared
with 1 µg of GST alone immobilized on glutathione-Sepharose (Amersham
Pharmacia Biotech), were incubated with each PTP-PEST GST fusion
proteins in 1 ml of HNMETG for 90 min at 4 °C. 200 µg of 293-T
extract was incubated with each p130Cas and paxillin GST
fusion proteins in 1 ml of HNMETG for 90 min at 4 °C. Following the
binding incubation, beads were washed three times in HNTG buffer (20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.1% Triton
X-100, 10% glycerol) and boiled in SDS sample buffer to elute bound
proteins. Following SDS-PAGE and transfer to PVDF membrane
(Immobilon-P), bound proteins were detected by Western blotting with
the appropriate antibodies.
Immunoprecipitations--
Cell monolayers were lysed in 1 ml of
immunoprecipitation buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1% Nonidet P-40, 1 mM
Na3VO4, and Complete protease inhibitors)
directly on the tissue culture dishes on ice for 15 min. The lysates
were cleared of cellular debris by centrifugation at 16 000 × g in a microcentrifuge. Aliquots (200-500 µg) of cell
extracts were precleared with 20 µl of Protein A-agarose (Life
Technologies, Inc.). The cleared extracts were incubated with 2 µl of
monoclonal anti-paxillin antibody or 1 µl of the polyclonal antibody
against avian paxillin for 90 min at 4 °C. Immune complexes were
recovered by addition of 20 µl of Protein A-agarose for 90 min at
4 °C. Immunoprecipitates were washed three times in
immunoprecipitation buffer and boiled in SDS-PAGE sample buffer.
Following SDS-PAGE and transfer to PVDF membranes, bound PTP-PEST was
detected by Western blotting using the anti-HA antibody 12CA5. Blots
were stripped and reblotted with the anti-paxillin antibody to verify
equal precipitations.
Western Blotting--
Nonspecific sites of blotted PVDF
membranes were blocked in TBS-T (20 mM Tris-HCl, pH 7.6, 137 mM NaCl, 0.1% Tween 20) containing 1% (w/v) bovine
serum albumin and 1% (v/v) goat serum for 60 min at room temperature.
Primary antibodies were diluted in blocking buffer and incubated with
blots for 60 min at room temperature. The monoclonal antibody
anti-paxillin was used at a dilution of 1:10,000. The monoclonal
antibodies 12CA5 and 4G10 were used at 1:2000 dilution. The monoclonal
antibodies anti-p130Cas, PY20, and PY99 were used at 1:1000
dilution. Blots were washed extensively with TBS-T before incubation
with the secondary antibody. The secondary anti-mouse antibody
conjugated to horseradish peroxidase was diluted 1:10000 in blocking
buffer and incubated with blots for 60 min at room temperature.
Following repeated washing in TBS-T, bound primary antibodies were
detected using chemiluminescence (NEN Life Science Products).
 |
RESULTS |
Paxillin Is Associated with PTP-PEST in Various Mouse
Tissues--
It was recently reported that PTP-PEST and paxillin
associate in chicken embryo fibroblasts and Swiss 3T3 cells (30). To verify that PTP-PEST and paxillin were physically associated in vivo, co-immunoprecipitation experiments were performed in lysates of various mouse tissues. As seen in Fig.
1, paxillin co-precipitated with PTP-PEST
in liver, brain, heart, lung, spleen, and thymus lysates. The highest
amounts of PTP-PEST-associated paxillin were found in lung, spleen, and
liver. No paxillin was detected in PTP-PEST immunoprecipitate from
kidney lysate, since PTP-PEST is expressed in low levels in kidney
(31). In addition, paxillin was not found in preimmune IP made from
liver extracts demonstrating the specificity of the association. When
the blot was reprobed with a PTP-PEST antibody, comparable amounts of
PTP-PEST were found in the precipitates except in the kidney where no
signal was detected (data not shown). These results demonstrate that the PTP-PEST-paxillin association described previously in fibroblasts (30) also occurs in vivo in a majority of mouse tissues.

View larger version (41K):
[in this window]
[in a new window]
|
Fig. 1.
Paxillin is associated with PTP-PEST in
various mouse tissues. PTP-PEST was immunoprecipitated from 1 mg
of liver, brain, heart, kidney, lung, spleen, and thymus lysates, and
the presence of associated paxillin was ascertained by Western blotting
using an antibody against paxillin. Paxillin was found in PTP-PEST
immunoprecipitations from liver, brain, heart, lung, spleen, and thymus
but not in kidney lysates. No paxillin was detected in preimmune
immunoprecipitation from liver lysate.
|
|
Paxillin Associates in Vitro with a Fragment of PTP-PEST Containing
a Proline-rich Region--
In order to define the region of PTP-PEST
involved in the binding of paxillin, we have used the non-catalytic
C-terminal tail of PTP-PEST in addition to several deletion mutants of
PTP-PEST expressed as GST fusion proteins (Fig.
2A). The GST PTP-PEST fusion proteins (aa 276-775, 276-613, 276-567, 276-453, and 276-437 or GST alone) bound to glutathione-Sepharose were incubated with 500 µg
of proteins extracted from NIH 3T3 cells. Following a binding incubation period, the beads were washed several times and bound proteins were separated by SDS-PAGE. Associated paxillin was detected by Western blotting. As seen in Fig. 2B (top
panel), paxillin was detected in every binding assay except
with GST alone. Coomassie Blue staining of the GST fusion proteins used
for the binding assay (Fig. 2B, bottom
panel) was used to demonstrate the integrity of the purified
proteins. From these results, the paxillin binding site lies between
amino acids 276-437 of PTP-PEST.

View larger version (36K):
[in this window]
[in a new window]
|
Fig. 2.
Pro 2 of PTP-PEST is required for paxillin
binding in NIH 3T3 cells. A, schematic representation
of the PTP-PEST GST fusion proteins used in the binding assays.
Deletion mutants (B) or proline-rich motifs (C)
of the PTP-PEST C terminus were incubated with NIH 3T3 cell lysate and
bound paxillin was monitored by Western blotting (top
panels). A Coomassie Blue-stained gel of the fusion proteins
used in the binding assay is shown in the bottom
panels of B and C.
|
|
The only characterized protein-binding domain within aa 276-437 of
PTP-PEST is a proline-rich region (Pro 1, 333PPKPPR337) that acts as binding site for the
SH3 domain of p130Cas, Hef1, Sin, and Grb2 (6, 9, 10). Also
present in this PTP-PEST fragment is Pro 2 (355PPEPHPVPPILTPSPPSAFP374), which is a
20-amino acid segment rich in proline residues that has no determined
function. In order to delimit the minimal region required for binding
to paxillin, a binding assay was thus performed using Pro 1, Pro 2 344-437, Pro 2 344-427, Pro 2 344-417, Pro 2 344 -407, Pro 2 344-397, and Pro 2 344-385 of PTP-PEST expressed as GST fusion
proteins (Fig. 2A). Paxillin was associated with the Pro 2 344-437, 344-427, 344-417, 344-407, and 344-397 PTP-PEST fusion
proteins (Fig. 2C, top panel). GST Pro
2 344-385, GST Pro 1, GST Pro 5, and GST alone failed to associate
with paxillin as seen in Fig. 2C (top
panel). These results suggest that amino acids 344-397 of
PTP-PEST are sufficient for its association with paxillin.
The Pro 2 Region of PTP-PEST Is Required for Paxillin Binding in
Vitro and in Vivo--
The Pro 2 domain of PTP-PEST lies between aa
355 and 374. Since the smallest GST Pro 2 fusion protein used in Fig.
1C encodes for aa 344-397, a PTP-PEST mutant lacking Pro 2 was generated to rigorously demonstrate its role in paxillin binding. A
binding assay was performed using two paxillin GST fusion proteins:
paxillin N (encoding for the LD motifs) and paxillin C (encoding for
the 4 LIM domains). These two proteins in addition to GST
p130Cas SH3 and GST alone were purified and incubated with
cell extracts of HEK 293T transfected either with WT or Pro 2 HA-PTP-PEST as described above. The bound PTP-PEST proteins were
monitored by Western blotting using the anti-HA antibody 12CA5. As
shown in Fig. 3A
(top panel), the GST paxillin C and
p130Cas SH3 were bound to WT HA PTP-PEST. The GST paxillin
N and GST alone failed to bind WT HA PTP-PEST. Five µg of HA WT
PTP-PEST-transfected HEK 293T extract were loaded to demonstrate the
proper expression of the transfected construct. When the same binding
assay was performed using Pro 2 HA PTP-PEST-transfected cell
extracts, GST paxillin C failed to bind Pro 2 PTP-PEST (Fig.
3A, top panel). The SH3 domain of
p130Cas was still capable of association with the Pro 2 mutant of PTP-PEST since it only requires an intact Pro 1 domain.
Pro 2 PTP-PEST was expressed to similar levels to WT as seen in the
TCL (5 µg of protein) lanes. To verify the presence and integrity of
the GST fusion proteins, the blots were stripped and probed with an anti-GST polyclonal antibody (Fig. 3A, bottom
panel). From these results, it is clear that the Pro 2 motif
of PTP-PEST is implicated in paxillin binding. In addition, the LIM
domains of paxillin rather than the LD motifs are implicated in the
association with PTP-PEST.

View larger version (45K):
[in this window]
[in a new window]
|
Fig. 3.
Pro 2 of PTP-PEST is essential for binding to
paxillin in vitro and in vivo.
A, HEK 293-T cells were transiently transfected with either
HA-WT or HA Pro 2 PTP-PEST. 200 µg of the indicated lysates were
incubated with either GST paxillin N, GST paxillin C, GST SH3
p130Cas, or GST alone. Bound PTP-PEST was monitored by
Western blotting with the anti-HA antibody 12CA5 (top
panel). 5 µg of TCL were also blotted with the 12CA5
antibody to verify comparable expression of HA-WT and HA- Pro 2 PTP-PEST. The presence and integrity of the GST fusion proteins was
verified by reprobing the blots with a polyclonal antibody against GST.
B, HEK 293T cells were transiently transfected with: mock
(empty pACTAG), HA-WT, HA- Pro1, or HA- Pro 2 PTP-PEST plasmids.
The proper expression of each construct was verified by immunoblotting
5 µg of TCL with the anti-HA antibody 12CA5 (top
panel). Paxillin was immunoprecipitated with a monoclonal
antibody and the presence of PTP-PEST was assessed by immunoblotting
with the anti-HA antibody 12CA5 (middle panel).
Equal precipitation of paxillin from each sample was verified by
reprobing the blot with a monoclonal antibody against paxillin
(bottom panel).
|
|
The importance of the Pro 2 domain of PTP-PEST for paxillin binding was
also confirmed in vivo in a co-immunoprecipitation experiment. HEK 293T cells were transfected with: mock (empty pACTAG),
HA WT PTP-PEST, HA Pro 1 PTP-PEST, or HA Pro 2 PTP-PEST. The
cells were lysed 48 h after transfection, and the expression of
the transfected constructs was monitored by Western blotting of TCL (5 µg) using the anti-HA antibody 12CA5 as seen in Fig. 3B
(top panel). Endogenous paxillin was then
immunoprecipitated with a monoclonal antibody. The presence of HA
PTP-PEST was assayed by blotting against the HA epitope using the 12CA5
antibody. Both the WT and Pro 1 PTP-PEST were found in paxillin
immunoprecipitates as seen in Fig. 3B (middle
panel). In accordance with the result shown in Fig.
3A, PTP-PEST lacking a Pro 2 was not found in paxillin immunoprecipitates (Fig. 3B, middle
panel). Equal precipitation of paxillin from each sample was
verified by stripping the blot and reprobing with an anti-paxillin
monoclonal antibody (Fig. 3B, bottom
panel).
Mutational Analysis of the Pro 2 Region Reveals the Importance of
Proline 362 for Paxillin Binding Activity--
The Pro 2 domain of
PTP-PEST is defined by 20 amino acids, half of which are proline
residues (Fig. 4A). Although
three PXXP motifs are found in the Pro 2, none of them have
the consensus sequence for SH3 binding sites (class 1, RXXPXXP; and class 2, PXXPXR) or WW domains (PPXY) (32).
Eight of the proline residues were individually mutated to alanine
(Fig. 3A) in the context of the GST Pro 2 344-437 construct
(see Fig. 2) in order to get a better understanding of this novel
paxillin binding domain. The WT GST Pro 2 as well as the eight proline
to alanine mutants were purified from induced bacterial cultures and
incubated with NIH 3T3 cell lysates. As seen in Fig. 4B,
paxillin was bound to all fusion proteins used except to the P362A
mutant. Equal amounts of GST fusion proteins as well as the integrity
of the products are shown in Fig. 4C. From these results, we
can conclude that the proline residue 362 is critical for binding to
paxillin.

View larger version (34K):
[in this window]
[in a new window]
|
Fig. 4.
Mutant P362A of Pro 2 on PTP-PEST abolishes
binding to paxillin in vitro. A,
schematic representation of the proline to alanine mutants of the GST
PTP-PEST Pro 2 construct (aa 344-437). The region shown represents the
paxillin binding site identified in Fig. 3. B, the GST Pro 2 as well as the eight proline to alanine mutants were purified and
incubated with 200 µg of NIH 3T3 cell lysate. Bound paxillin was
monitored by immunoblotting with a monoclonal antibody against
paxillin. C, to verify expression as well as integrity of
the fusion proteins used in the binding assay, an aliquot of each
binding assay was separated by SDS-PAGE and the gel was stained with
Coomassie Blue.
|
|
The LIM Domains 3 and 4 of Paxillin Are Required for PTP-PEST
Binding--
Having delimited the region on PTP-PEST important for
binding to paxillin, we were next interested in mapping the segment of
paxillin required for its association to PTP-PEST. A GST fusion protein
encoding the four LIM domains of paxillin was demonstrated to have the
PTP-PEST binding activity (Fig. 2A). A panel of GST fusion
proteins of paxillin LIM domains was generated in order to investigate
which LIM domain is important for PTP-PEST binding. A schematic
representation of these constructs is shown in Fig. 5A. These fusion proteins were
purified from induced bacterial cultures and incubated with HA-PTP-PEST
expressing 293T cell lysates. Bound PTP-PEST was detected by Western
blotting using the anti-HA antibody 12CA5. As seen in Fig.
5B, the paxillin C terminus (paxillin C, LIM 1-4) was bound
to PTP-PEST. The C-terminal deletion mutants (LIM 1-3, LIM
1-4 LIM3, and LIM 1-2) as well as the LIM domains expressed
separately failed to bind PTP-PEST. Interestingly, the LIM 3-4
construct was the only deletion construct retaining PTP-PEST binding
activity (Fig. 5B). GST alone used as a negative control was
not capable of precipitating PTP-PEST. To demonstrate proper expression
of each construct as well as the integrity of the products, a Coomassie
Blue-stained gel representative of the GST fusion proteins used in the
binding assay is shown in Fig. 5C.

View larger version (24K):
[in this window]
[in a new window]
|
Fig. 5.
LIM domains 3 and 4 of paxillin are required
for binding to PTP-PEST in vitro. A, schematic
representation of a panel of paxillin LIM domains GST fusion proteins
used to identify the PTP-PEST binding site. B, the paxillin
GST fusion proteins were purified and incubated with HEK 293T cell
lysates transiently expressing HA-PTP-PEST. Bound PTP-PEST was detected
by immunoblotting with the anti-HA antibody 12CA5 (top
panel). The expression as well as the integrity of each
fusion protein used in the binding assay was verified by Coomassie Blue
staining of a gel containing the resolved proteins.
|
|
It is possible that only one of the LIM domains (3 or 4) is interacting
with PTP-PEST, but both may be required to have a biologically active
conformation. This may be an important concern especially since the
fusion proteins have been expressed in bacteria. In order to test this
hypothesis, co-immunoprecipitation experiments were performed between
PTP-PEST and full-length paxillin WT, LIM3, or LIM4 mutants. HEK
293T cells were co-transfected with HA PTP-PEST and either pcDNA3
(empty), pcDNA3 WT, LIM 3, or LIM4 avian paxillin. Five µg
aliquots of each sample was analyzed by Western blotting to verify
PTP-PEST expression (Fig. 6C).
Aliquots of each lysate were immunoprecipitated with an antibody
specific for avian paxillin. The presence of PTP-PEST in the paxillin
precipitates was investigated by Western blotting using the anti-HA
antibody 12CA5. As seen in Fig. 6A, PTP-PEST was detected
after precipitation of WT paxillin but not either of the LIM 3 or 4 deletion mutants. To verify equal precipitation of paxillin in each
sample, the blot was stripped and reprobed with a monoclonal antibody
against paxillin. As seen in Fig. 6B, equal amounts of
paxillin were detected in all samples except in the negative
control (pcDNA3, Fig. 6B).

View larger version (42K):
[in this window]
[in a new window]
|
Fig. 6.
LIM domains 3 and 4 of paxillin are required
for binding to PTP-PEST in vivo. HEK 293-T cells
were transiently co-transfected with HA-PTP-PEST and either pcDNA3,
WT, LIM3, or LIM4 avian paxillin. A, 48 h after
transfection, paxillin was immunoprecipitated from each lysates with a
avian specific polyclonal antibody and the co-precipitation of PTP-PEST
was assayed by immunoblotting with the anti-HA antibody 12CA5.
B, the blot was reprobed with a monoclonal antibody against
paxillin to verify equal precipitation. No paxillin was detected in the
empty vector (pcDNA3) sample. C, HA-PTP-PEST expression
levels were monitored from each transfection by immunoblotting 5 µg
of TCL with the anti-HA antibody 12CA5.
|
|
Intact LIM 3 and LIM 4 Are Required for Binding to
PTP-PEST--
In order to confirm that both LIM 3 and LIM 4 domains of
paxillin participate in PTP-PEST binding, point mutations were
introduced in these domains. Each LIM domain is composed of two zinc
fingers stabilized by critical cysteine, histidine, or aspartic acid
residues (19). The C467A and the C470A mutants disrupt the first and the second zinc finger of the LIM 3 domain, respectively, and the
C467/470A is a double mutant. The C523S disrupts the first zinc finger
of LIM 4. The WT paxillin and all the mutants were in vitro
translated in the presence of [35S]methionine. These
products were then incubated with GST PTP-PEST Pro 2 (344-397). As
seen in Fig. 7 (top
panel), only the WT paxillin was able to interact with the
PTP-PEST GST fusion proteins. As a control, GST alone did not interact
with WT paxillin (last lane, top
panel). In the bottom panel, 15% of
the amount of each product used in the binding assays is shown to
demonstrate the integrity of the products and also as a loading
control. These data clearly demonstrate that the integrity of both LIM
3 and LIM 4 is critical for binding to PTP-PEST.

View larger version (53K):
[in this window]
[in a new window]
|
Fig. 7.
Intact LIM 3 and LIM 4 of paxillin are
required for binding to PTP-PEST. pcDNA3, WT, or mutant
paxillin ( LIM 3, C467A, C470A, C467/470A, LIM4, and C523S) were
in vitro translated in the presence of
[35S]methionine. These in vitro translated
products were incubated with GST-PTP-PEST Pro 2 (344-397). Following
repeated washes of the GST matrix, bound proteins were separated on
10% SDS-PAGE and bound proteins were visualized by a 8-h exposure to
film (top panel). GST alone was incubated with WT
paxillin and serves as a negative control. In the bottom
panel, 15% of the amount of each paxillin products used in
the binding assay demonstrate integrity of the products (8-h
exposure).
|
|
Paxillin Is Not a Substrate for PTP-PEST--
Since paxillin is a
tyrosine-phosphorylated protein, a substrate trapping approach (7, 8,
10) using C231S mutants of the catalytic domain of PTP-PEST, was used
to investigate if paxillin is a physiological substrate for PTP-PEST.
The substrate trapping mutants used were GST 1-453 C231S (containing
Pro 2) and GST 1-354 C231S (Pro 2 is deleted) PTP-PEST fusion
proteins. Protein extracts were prepared from control NIH 3T3, NIH 3T3
stably expressing Src Y527F, and pervanadate-treated NIH 3T3 cells.
These samples were incubated with either PTP-PEST C terminus (aa
276-775), PTP-PEST 1-453 WT, PTP-PEST 1-453 C231S, or PTP-PEST
1-354 C231S expressed as GST fusion proteins. Tyrosine-phosphorylated
proteins precipitating with PTP-PEST GST fusion proteins were
visualized by immunoblotting with an anti-phosphotyrosine antibody. As
seen in Fig. 8A, in the Src
Y527F and pervanadate (PV)-treated cells, a protein of 130 kDa is the
major tyrosine-phosphorylated protein bound to the C231S mutants of
PTP-PEST. This protein is known to be p130Cas (8, 10) and
thus serves as a control to ensure that the trapping experiment worked,
as seen by blotting with an anti-p130Cas antibody in Fig.
8C. The 60-kDa band detected in the PTP-PEST 1-354 C231S
lanes is the GST fusion protein cross-reacting in a nonspecific manner
with the PY99 anti-phosphotyrosine antibody. In NIH 3T3 and NIH 3T3 Src
527F cells, a 70-kDa tyrosine-phosphorylated protein was detected in
the PTP-PEST C terminus, 1-453 WT, and C231S but not in the 1-354
C231S. This p70 protein was identified as paxillin when the blot was
reprobed with an anti-paxillin monoclonal antibody (Fig.
8B). Importantly, no paxillin was detected in the GST
PTP-PEST 1-354 C231S lanes, the only construct lacking the Pro 2, thus
unambiguously showing that the PTP-PEST catalytic domain is not
interacting directly with tyrosine-phosphorylated paxillin. This result
clearly demonstrates that paxillin is not a substrate for the PTP-PEST
catalytic domain in a substrate trapping assay. Interestingly, when 3T3
cells are treated with pervanadate, only a small amount of
paxillin is detected (overexposure of the blot, data not shown) bound
to the PTP-PEST fusion proteins having the Pro 2. This suggest that
hyperphosphorylation of paxillin on tyrosine residues could prevent
binding to PTP-PEST. The integrity of each fusion protein used in the
trapping assay was verified by Coomassie Blue staining of the PVDF
blots as seen in Fig. 8D.

View larger version (71K):
[in this window]
[in a new window]
|
Fig. 8.
Paxillin is not a substrate for
PTP-PEST. Lysates of NIH 3T3, NIH 3T3 expressing Src Y527F, and
NIH 3T3 treated with pervanadate were incubated with four different
PTP-PEST GST fusion proteins: C terminus (aa 276-775),
1-453 WT, 1-453 C231S, and 1-354 C231S. A, bound proteins
were resolved by SDS-PAGE and tyrosine-phosphorylated proteins were
detected by immunoblotting with an anti-phosphotyrosine antibody. The
blot was reprobed with anti-paxillin (B) and
anti-p130Cas (C) monoclonal antibodies.
D, the expression and integrity of each fusion proteins was
verified by Coomassie Blue staining of the PVDF blots.
|
|
 |
DISCUSSION |
In a recent report, Shen et al. (30) demonstrated that
FAK complexes with proteins having protein-tyrosine phosphatase
activity (PTP). One of these PTPs, PTP-PEST, was found in FAK complexes via a direct association with paxillin (30). These findings are
significant since they suggest a dynamic regulation of protein-tyrosine phosphorylation in focal adhesions. In support of this hypothesis, fibroblasts lacking FAK (33) or PTP-PEST (14) exhibit migration defects
and a higher number of focal adhesions indicating that both tyrosine
kinases and phosphatases have an active function in the assembly and
disassembly of these adhesive cellular structures. We have analyzed the
binding of PTP-PEST to paxillin in order to get a better understanding
of the function of PTP-PEST in the regulation of focal adhesion turnover.
The co-precipitation of paxillin and PTP-PEST was reported in chicken
embryo and Swiss 3T3 cultured fibroblasts (30). We demonstrate that the
association between paxillin and PTP-PEST is physiologically relevant
since both proteins co-precipitate from a variety of normal mouse
tissues namely liver, brain, heart, lung, spleen, and thymus (Fig. 1).
Paxillin was not detected in PTP-PEST precipitate from kidney since
PTP-PEST is poorly expressed in kidney as shown previously (31).
In this study, we have identified the domains in PTP-PEST and paxillin
that are responsible for their association. Our present data
demonstrate that in vitro, a segment of PTP-PEST from aa 344-397 was sufficient for binding paxillin. In vivo, a
proline-rich motif on PTP-PEST, Pro 2 (355PPEPHPVPPILTPSPPSAFP374), is essential for
binding to paxillin. In addition, intact LIM 3 and LIM 4 domains of
paxillin are required for binding to PTP-PEST. Furthermore,
tyrosine-phosphorylated paxillin was not able to complex with a
substrate trapping mutant of PTP-PEST (C231S) lacking the Pro 2, demonstrating that it is not a physiological substrate of PTP-PEST in
this "substrate trapping" type of assay. The catalytic domain of
PTP-PEST is flanked by a C-terminal tail rich in protein binding
motifs. In this respect, the SH3 domains of p130Cas, Hef1,
Sin/Efs (10, 34), Grb2, v-Src (6), and Csk (31) have been shown to
directly associate with proline-rich sequences in PTP-PEST. In
addition, the coiled-coil domain of PSTPIP also associates with a
non-classical polyproline-rich domain of PTP-PEST (35) and the PTB
domain of Shc was shown to bind a NPLH motif on PTP-PEST (5). The Pro 2 of PTP-PEST contains none of the consensus sequences that can act as
ligands for either SH3 or WW domains. This suggests that the Pro 2 of
PTP-PEST is a novel protein binding motif that can associate with LIM
domains of at least paxillin. Interestingly, Pro 2 is conserved between
human and mouse PTP-PEST but is not present on other members of the PTP-PEST family of enzymes (PEP, PTP-HSCF, and PTP20). One concern is
that the Pro 2 deletion, which prevents paxillin binding, might produce
a misfolded PTP-PEST. However, this hypothesis is unlikely since
p130Cas can still interact with PTP-PEST Pro 2 through
an SH3-Pro 1 association (Fig. 3A). In addition,
site-directed mutagenesis analysis demonstrated that Proline 362 is
critical for binding to paxillin, whereas seven other proline mutants
had little if no effect on paxillin binding. To gain a better
understanding of the Pro 2, experiments involving more point mutations
of residues surrounding Pro-362 and a NMR structure determination of
the peptide bound to its paxillin partner are currently under
investigation.2
Paxillin is an adaptor protein composed entirely of protein binding
modules including LD, LIM, SH2 binding sites, and proline-rich domains.
Our results indicate that only LIM 3 and LIM 4 are essential for
PTP-PEST binding activity. When expressed as GST fusion proteins, neither LIM 3 nor LIM 4 alone was able to negotiate binding with PTP-PEST whereas a construct containing both LIM 3 and LIM 4 domains supports the association. It is possible that LIM 3 and LIM 4 do not
fold properly when expressed in bacteria; however, a recent report by
Brown et al. (25) indicates that GST LIM 2 and LIM 3 alone
associate with serine and threonine kinases, suggesting that they are
properly folded domains (25). We have also observed that, in
vivo, full-length paxillin lacking either LIM 3 or LIM 4 was
unable to bind to PTP-PEST. In addition, we have clearly demonstrated
that point mutation that disrupt the zinc fingers in either LIM 3 or
LIM 4 of paxillin prevents binding to PTP-PEST. Together, these data
point to LIM 3 and LIM 4 as critical domains for paxillin association
with PTP-PEST.
LIM domains ligands are extremely varied (27, 28). For example, some
LIM domains have been shown to heterodimerize while others bind to
structurally distinct protein motifs (27). Among others, it has been
previously shown that the LIM 3 of Enigma associates with a
tyrosine-based motif (tyrosine tight turn) of the chain of the
insulin receptor (29). Interestingly, the tyrosine tight turn of the
insulin receptor (GPLGPLYA) contains a PXXP motif and
mutation of the two prolines to alanines abolishes binding to the LIM 3 of Enigma (29). Furthermore, when the LIM 3 of Enigma was used to
screen a random peptide library with a fixed tyrosine (position 0),
prolines at position 1 and +2 were favored. A consensus sequence for
the preferred ligand of the LIM 3 of Enigma was determined:
GPHydGPLHyd(Y/F)A (Hyd=hydrophobic residue). Our data demonstrate that
the Pro 2 of PTP-PEST,
355PPEPHPVPPILTPSPPSAFP374, is the
binding site for paxillin and that Pro-362 (in bold) is critical for
the association. The consensus ligand sequence for the LIM 3 of Enigma
is not found in PTP-PEST Pro 2. LIM 3 and LIM 4 of paxillin thus
associates with a novel polyproline motif, and adds to the wide variety
of LIM domain ligands. The discovery of other ligands for LIM 3 and LIM
4 of paxillin and their comparison to the PTP-PEST Pro 2 will allow the
elaboration of a preferred ligand sequence for these LIM domains.
In parallel to this work, PTP-PEST has also been reported to associate
with the paxillin homologue Hic-5 (36). The C-terminal LIM domains of
Hic-5 is 68% similar to the LIM domains of paxillin. It was shown that
the LIM 3 of Hic-5 is the most important for the binding to PTP-PEST
but is still not sufficient. Surprisingly, LIM 4 was not critical for
the binding of Hic-5 to PTP-PEST. In addition, point mutations in the
zinc finger of either LIM 3 or LIM 4 of Hic-5 did not prevent
association with PTP-PEST in a co-precipitation experiment. These
results differ from the one observed in the association between
PTP-PEST and paxillin, and suggest that even though the LIM domains of
Hic-5 and paxillin are 68% similar, the mechanism of binding to
PTP-PEST is not identical.
PTP-PEST has been shown to be very selective for its physiological
substrates (8, 10). The selectivity toward p130Cas can be
explained by the fact that both a substrate recognition by the PTP
domain and a SH3-mediated association occur before dephosphorylation.
An important issue that needed to be resolved in order to understand
the significance of paxillin-PTP-PEST association was to clarify if
paxillin is a substrate for PTP-PEST. Our data clearly demonstrates
that tyrosine-phosphorylated paxillin was not bound to a PTP-PEST C231S
mutant lacking the Pro 2, indicating that paxillin is not directly
recognized by the PTP domain. In addition, equal amounts of paxillin
were also found in the precipitates of GST PTP-PEST WT or C231S and
paxillin was not found to be more tyrosine-phosphorylated in the C231S
samples, suggesting an absence of cooperation between the catalytic
domain and the Pro 2 (Fig. 8C). In support of these
findings, Garton and Tonks (16) have demonstrated that overexpression
of PTP-PEST in Rat-1 fibroblasts prevents cells from migrating in a
wound healing assay. In these cells, p130Cas
phosphotyrosine level was greatly reduced whereas paxillin and FAK
tyrosine phosphorylation levels were unaltered (16). Thus, these
results also indicate that paxillin is not a target for PTP-PEST.
Other PTPs were reported to have remarkable specificity toward
substrates including PTP1B (7, 37), T cell-PTP (38), and SHP-1 (39). In
contrast, the presence of the PSTPIP binding motif on PTP-HSCF was
demonstrated to be essential for a specific tyrosine dephosphorylation
of PSTPIP since the PTP domain alone did not dephosphorylate PSTPIP
(35). Because we based our conclusions only on a substrate trapping
approach, it remains a possibility that paxillin is a weak substrate
for PTP-PEST in vivo. It is also possible that the formation
of some protein complexes could favor paxillin dephosphorylation by
PTP-PEST. In a in vitro dephosphorylation assay,
GST-PTP-PEST dephosphorylated weakly a paxillin peptide compared with a
p130Cas peptide.3
The known promiscuous activity of PTPases in vitro prevents
us from basing our substrate identification using such an assay.
If paxillin is not a substrate for PTP-PEST, what is the physiological
significance of paxillin-PTP-PEST association? A first clue to answer
this question came from findings by Brown et al. (19),
indicating that the intracellular localization of paxillin depends on
the association of a yet unknown binding protein to the LIM 3 of
paxillin. A reasonable assumption is that this LIM 3 ligand must
co-localize with paxillin in focal contact sites. PTP-PEST is most
likely not the protein responsible for paxillin focal adhesion
localization since it is found mainly in the cytoplasm. We have
demonstrated in a previous study that PTP-PEST can translocate to the
membrane periphery following integrin engagement (14). Hence, we
propose a model where PTP-PEST is translocated (14) to focal adhesions
and associates with paxillin (Fig.
9A). This would allow the
SH3-mediated association with focal adhesion located p130Cas and inhibit its downstream signaling via
dephosphorylation of residues of p130Cas critical tyrosine
residues. Importantly, the LIM 3 of paxillin would be negotiating to
bind with the Pro 2 of PTP-PEST instead of associating with its ligand
that is essential for focal adhesion targeting (19). The SH3 domain of
p130Cas has also been shown to be critical for proper focal
adhesion targeting of p130Cas (40) probably via its
association with p125FAK. In a similar manner to the LIM 3 of paxillin, the SH3 domain of p130Cas would be bound to
the Pro 1 of PTP-PEST instead of p125FAK. Together, this
cascade would result in the release of paxillin and p130Cas
from focal adhesion complexes in addition to p130Cas
tyrosine dephosphorylation as seen in Fig. 9B. The
additional recruitment of Csk via a direct association to PTP-PEST (31) would result in the phosphorylation of the inhibitory site of Src, thus
inhibiting the formation of new focal adhesions. Our findings that
PTP-PEST knock-out cells accumulate large numbers of focal adhesions
suggest that the most important function for PTP-PEST is to promote
focal adhesion disassembly, hence the turnover of focal adhesion
complexes (14). Therefore, we propose that PTP-PEST promotes focal
adhesion turnover via its tyrosine phosphatase activity toward
p130Cas and via direct binding to critical domains of
p130Cas and paxillin required for focal adhesion
targeting.

View larger version (24K):
[in this window]
[in a new window]
|
Fig. 9.
Model for PTP-PEST functions in the
disassembly of focal adhesions. A, simplified model of
the proteins involved in focal adhesions. PTP-PEST is recruited to
focal adhesions by a yet unknown mechanism (14). It can then bind to
LIM 3 and 4 of paxillin and subsequently to the SH3 domain of
p130Cas and dephosphorylate tyrosine residues
(pY) on p130Cas essential for binding SH2 domain
containing protein (such as Crk). By dephosphorylating
p130Cas, PTP-PEST is believed to inhibit downstream
signaling from Src, SOS, and C3G. Csk associated to PTP-PEST can also
inhibit Src by phosphorylating the negative regulatory sites of Src.
B, the consequence of PTP-PEST recruitment to focal
adhesions is the binding to paxillin and p130Cas. Both the
LIM 3 of paxillin (19) and the SH3 domain of p130Cas (40)
are essential for targeting these proteins to focal adhesion. By
binding to PTP-PEST, we propose that both of these proteins would
relocate to the cytoplasm. Focal adhesion formation is further
inhibited by the inactivation of Src activity by PTP-PEST-associated
Csk. These events implicating PTP-PEST would favor the breakdown of
focal adhesions and enable cell migration before focal adhesions are
reassembled.
|
|
 |
ACKNOWLEDGEMENTS |
We are grateful to Dr. Kiyoshi Nose for
helpful discussions. We are also thankful to John Wagner, Eva
Michaliszyn, Ailsa Lee Loy, and Joseph Perrotta for their technical
assistance. We also thank Dr. Alain Charest for plasmid reagents. We
are also indebted to Dr. Louise Larose, John Wagner, Alan Cheng, and
Alexandre Angers-Loustau (McGill University, Montréal,
Québec, Canada) for critical reading of the manuscript. We thank
Dr. Alan D. Agulnick and Dr. Heiner Westphal for the gift of LIM
domains reagents.
 |
FOOTNOTES |
*
This work was supported in part by a grant from the Medical
Research Council of Canada (to M. L. T.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
§
Recipient of a Cancer Research Society studentship.
Established investigator of the American Heart Association.
Supported by National Institutes of Health Grant GM47607.
**
Chercheur boursier from les Fonds de la Recherche en Santé du
Québec. To whom correspondence should be addressed: McGill University, 3655 Drummond St., Montreal, Quebec H3G 1Y6, Canada. Tel.:
514-398-7290; Fax: 514-398-7384; E-mail: tremblay@med.mcgill.ca.
2
J. F. Côté, C. E. Turner,
M. L. Tremblay, and K. Gehring, unpublished data.
3
J. F. Côté and M. L. Tremblay, unpublished observations.
 |
ABBREVIATIONS |
The abbreviations used are:
PTP, protein-tyrosine phosphatase;
aa, amino acid(s);
TCL, total cell
lysate;
HA, hemagglutinin epitope;
p125FAK, focal adhesion
kinase;
p130Cas, p130 Crk-associated substrate;
GST, glutathione S-transferase;
PCR, polymerase chain reaction;
SH, Src homology;
PAGE, polyacrylamide gel electrophoresis;
IP, immunoprecipitation;
WT, wild type;
PVDF, polyvinylidene difluoride;
TBS-T, Tris-buffered saline with Tween 20.
 |
REFERENCES |
| 1.
|
Neel, B. G.,
and Tonks, N. K.
(1997)
Curr. Opin. Cell Biol.
9,
193-204[CrossRef][Medline]
[Order article via Infotrieve]
|
| 2.
|
Tonks, N. K.,
and Neel, B. G.
(1996)
Cell
87,
365-368[CrossRef][Medline]
[Order article via Infotrieve]
|
| 3.
|
Charest, A.,
Wagner, J.,
Shen, S. H.,
and Tremblay, M. L.
(1995)
Biochem. J.
308,
425-432
|
| 4.
|
Habib, T.,
Herrera, R.,
and Decker, S. J.
(1994)
J. Biol. Chem.
269,
25243-25246[Abstract/Free Full Text]
|
| 5.
|
Charest, A.,
Wagner, J.,
Jacob, S.,
McGlade, C. J.,
and Tremblay, M. L.
(1996)
J. Biol. Chem.
271,
8424-8429[Abstract/Free Full Text]
|
| 6.
|
Charest, A.,
Wagner, J.,
Kwan, M.,
and Tremblay, M. L.
(1997)
Oncogene
14,
1643-1651[CrossRef][Medline]
[Order article via Infotrieve]
|
| 7.
|
Flint, A. J.,
Tiganis, T.,
Barford, D.,
and Tonks, N. K.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
1680-1685[Abstract/Free Full Text]
|
| 8.
|
Garton, A. J.,
Flint, A. J.,
and Tonks, N. K.
(1996)
Mol. Cell. Biol.
16,
6408-6418[Abstract]
|
| 9.
|
Garton, A. J.,
Burnham, M. R.,
Bouton, A. H.,
and Tonks, N. K.
(1997)
Oncogene
15,
877-885[CrossRef][Medline]
[Order article via Infotrieve]
|
| 10.
|
Côté, J. F.,
Charest, A.,
Wagner, J.,
and Tremblay, M. L.
(1998)
Biochemistry
37,
13128-13137[CrossRef][Medline]
[Order article via Infotrieve]
|
| 11.
|
Tachibana, K.,
Urano, T.,
Fujita, H.,
Ohashi, Y.,
Kamiguchi, K.,
Iwata, S.,
Hirai, H.,
and Morimoto, C.
(1997)
J. Biol. Chem.
272,
29083-29090[Abstract/Free Full Text]
|
| 12.
|
Hanks, S. K.,
and Polte, T. R.
(1997)
Bioessays
19,
137-145[CrossRef][Medline]
[Order article via Infotrieve]
|
| 13.
|
Clark, E. A.,
and Brugge, J. S.
(1995)
Science
268,
233-239[Abstract/Free Full Text]
|
| 14.
|
Angers-Loustau, A.,
Côté, J.-F.,
Charest, A.,
Dowbenko, D.,
Spencer, S.,
Lasky, L. A.,
and Tremblay, M. L.
(1999)
J. Cell Biol.
144,
1019-1031[Abstract/Free Full Text]
|
| 15.
|
Lauffenburger, D. A.,
and Horwitz, A. F.
(1996)
Cell
84,
359-369[CrossRef][Medline]
[Order article via Infotrieve]
|
| 16.
|
Garton, A. J.,
and Tonks, N. K.
(1999)
J. Biol. Chem.
274,
3811-3818[Abstract/Free Full Text]
|
| 17.
|
Shibanuma, M.,
Mochizuki, E.,
Maniwa, R.,
Mashimo, J.,
Nishiya, N.,
Imai, S.,
Takano, T.,
Oshimura, M.,
and Nose, K.
(1997)
Mol. Cell. Biol.
17,
1224-1235[Abstract]
|
| 18.
|
Lipsky, B. P.,
Beals, C. R.,
and Staunton, D. E.
(1998)
J. Biol. Chem.
273,
11709-11713[Abstract/Free Full Text]
|
| 19.
|
Brown, M. C.,
Perrotta, J. A.,
and Turner, C. E.
(1996)
J. Cell Biol.
135,
1109-1123[Abstract/Free Full Text]
|
| 20.
|
Tachibana, K.,
Sato, T., N., D. A.,
and Morimoto, C.
(1995)
J. Exp. Med.
182,
1089-1099[Abstract/Free Full Text]
|
| 21.
|
Turner, C. E.,
and Miller, J. T.
(1994)
J. Cell Sci.
107,
1583-1591[Abstract]
|
| 22.
|
Schaller, M. D.,
and Parsons, J. T.
(1995)
Mol. Cell. Biol.
1,
2635-2645
|
| 23.
|
Bellis, S. L.,
Miller, J. T.,
and Turner, C. E.
(1995)
J. Biol. Chem.
270,
17437-17441[Abstract/Free Full Text]
|
| 24.
|
Bellis, S. L.,
Perrotta, J. A.,
Curtis, M. S.,
and Turner, C. E.
(1997)
Biochem. J.
325,
375-381
|
| 25.
|
Brown, M. C.,
Perrotta, J. A.,
and Turner, C. E.
(1998)
Mol. Biol. Cell.
9,
1803-1816[Abstract/Free Full Text]
|
| 26.
|
Brown, M. C.,
Curtis, M. S.,
and Turner, C. E.
(1998)
Nat. Struct. Biol.
5,
677-678[CrossRef][Medline]
[Order article via Infotrieve]
|
| 27.
|
Dawid, I. B.,
Breen, J. J.,
and Toyama, R.
(1998)
Trends Genet.
14,
156-162[CrossRef][Medline]
[Order article via Infotrieve]
|
| 28.
|
Sanchez-Garcia, I.,
and Rabbitts, T. H.
(1994)
Trends Genet.
10,
315-320[CrossRef][Medline]
[Order article via Infotrieve]
|
| 29.
|
Wu, R.,
Durick, K.,
Zhou, S.,
Cantley, L. C.,
Taylor, S. S.,
and Gill, G. N.
(1996)
J. Biol. Chem.
271,
15934-15941[Abstract/Free Full Text]
|
| 30.
|
Shen, Y.,
Schneider, G.,
Cloutier, J.-F.,
Veillette, A.,
and Schaller, M. D.
(1998)
J. Biol. Chem.
273,
6474-6481[Abstract/Free Full Text]
|
| 31.
|
Davidson, D.,
Cloutier, J.-F.,
Gregorieff, A.,
and Veillette, A.
(1997)
J. Biol. Chem.
272,
23455-23462[Abstract/Free Full Text]
|
| 32.
|
Chen, H. I.,
Einbond, A.,
Kwak, S.-J.,
Linn, H.,
Koepf, E.,
Peterson, S.,
Kelly, J. W.,
and Sudol, M.
(1997)
J. Biol. Chem.
272,
17070-17077[Abstract/Free Full Text]
|
| 33.
|
Ilìc, D.,
Furuta, Y.,
Kanazawa, S.,
Takeda, N.,
Sobue, K.,
Nakatsuji, N.,
Nomura, S.,
Fujimoto, J.,
Okada, M.,
and Yamamoto, T.
(1995)
Nature
377,
539-544[CrossRef][Medline]
[Order article via Infotrieve]
|
| 34.
|
Garton, A. J.,
Burnham, M. R.,
Bouton, A. H.,
and Tonks, N. K.
(1997)
Oncogene
15,
877-885
|
| 35.
|
Spencer, S.,
Dowbenko, D.,
Cheng, J.,
Li, W. L.,
Brush, J.,
Utzig, S.,
Simanis, V.,
and Lasky, L. A.
(1997)
J. Cell Biol.
138,
845-860[Abstract/Free Full Text]
|
| 36.
|
Nishiya, N.,
Iwabuchi, Y.,
Shibanuma, M.,
Côté, J.-F.,
Tremblay, M.,
and Nose, K.
(1999)
J. Biol. Chem.
274,
9847-9853[Abstract/Free Full Text]
|
| 37.
|
Liu, F.,
Hill, D. E.,
and Chernoff, J.
(1996)
J. Biol. Chem.
271,
31290-31295[Abstract/Free Full Text]
|
| 38.
|
Tiganis, T.,
Bennett, A. M.,
Ravichandran, K. S.,
and Tonks, N. K.
(1998)
Mol. Cell. Biol.
18,
1622-1634[Abstract/Free Full Text]
|
| 39.
|
Timms, J. F.,
Carlberg, K.,
Gu, H.,
Chen, H.,
Kamatkar, S.,
Nadler, M. J.,
Rohrschneider, L. R.,
and Neel, B. G.
(1998)
Mol. Cell. Biol.
18,
3838-3850[Abstract/Free Full Text]
|
| 40.
|
Nakamoto, T.,
Sakai, R.,
Honda, H.,
Ogawa, S.,
Ueno, H.,
Suzuki, T.,
Aizawa, S.,
Yazaki, Y.,
and Hirai, H.
(1997)
Mol. Cell. Biol.
17,
3884-3897[Abstract]
|
Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
N. K. Zouq, J. A. Keeble, J. Lindsay, A. J. Valentijn, L. Zhang, D. Mills, C. E. Turner, C. H. Streuli, and A. P. Gilmore
FAK engages multiple pathways to maintain survival of fibroblasts and epithelia - differential roles for paxillin and p130Cas
J. Cell Sci.,
February 1, 2009;
122(3):
357 - 367.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. O. Deakin and C. E. Turner
Paxillin comes of age
J. Cell Sci.,
August 1, 2008;
121(15):
2435 - 2444.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Wade, N. Brimer, and S. Vande Pol
Transformation by Bovine Papillomavirus Type 1 E6 Requires Paxillin
J. Virol.,
June 15, 2008;
82(12):
5962 - 5966.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Halle, Y.-C. Liu, S. Hardy, J.-F. Theberge, C. Blanchetot, A. Bourdeau, T.-C. Meng, and M. L. Tremblay
Caspase-3 Regulates Catalytic Activity and Scaffolding Functions of the Protein Tyrosine Phosphatase PEST, a Novel Modulator of the Apoptotic Response
Mol. Cell. Biol.,
February 1, 2007;
27(3):
1172 - 1190.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. P. Playford, P. D. Lyons, S. K. Sastry, and M. D. Schaller
Identification of a Filamin Docking Site on PTP-PEST
J. Biol. Chem.,
November 10, 2006;
281(45):
34104 - 34112.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. McGarrigle, D. Shan, S. Yang, and X.-Y. Huang
Role of Tyrosine Kinase Csk in G Protein-coupled Receptor- and Receptor Tyrosine Kinase-induced Fibroblast Cell Migration
J. Biol. Chem.,
April 14, 2006;
281(15):
10583 - 10588.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. S. Jamieson, D. A. Tumbarello, M. Halle, M. C. Brown, M. L. Tremblay, and C. E. Turner
Paxillin is essential for PTP-PEST-dependent regulation of cell spreading and motility: a role for paxillin kinase linker
J. Cell Sci.,
December 15, 2005;
118(24):
5835 - 5847.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. A. Tumbarello, M. C. Brown, S. E. Hetey, and C. E. Turner
Regulation of paxillin family members during epithelial-mesenchymal transformation: a putative role for paxillin {delta}
J. Cell Sci.,
October 15, 2005;
118(20):
4849 - 4863.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. C. Brown, L. A. Cary, J. S. Jamieson, J. A. Cooper, and C. E. Turner
Src and FAK Kinases Cooperate to Phosphorylate Paxillin Kinase Linker, Stimulate Its Focal Adhesion Localization, and Regulate Cell Spreading and Protrusiveness
Mol. Biol. Cell,
September 1, 2005;
16(9):
4316 - 4328.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y.-J. Lai, C.-S. Chen, W.-C. Lin, and F.-T. Lin
c-Src-Mediated Phosphorylation of TRIP6 Regulates Its Function in Lysophosphatidic Acid-Induced Cell Migration
Mol. Cell. Biol.,
July 15, 2005;
25(14):
5859 - 5868.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. C. Brown and C. E. Turner
Paxillin: Adapting to Change
Physiol Rev,
October 1, 2004;
84(4):
1315 - 1339.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Y. Romanova, S. Hashimoto, K.-O. Chay, M. V. Blagosklonny, H. Sabe, and J. F. Mushinski
Phosphorylation of paxillin tyrosines 31 and 118 controls polarization and motility of lymphoid cells and is PMA-sensitive
J. Cell Sci.,
August 1, 2004;
117(17):
3759 - 3768.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J.-F. Cote and K. Vuori
Identification of an evolutionarily conserved superfamily of DOCK180-related proteins with guanine nucleotide exchange activity
J. Cell Sci.,
March 14, 2003;
115(24):
4901 - 4913.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. A. Grace and J. Busciglio
Aberrant Activation of Focal Adhesion Proteins Mediates Fibrillar Amyloid beta -Induced Neuronal Dystrophy
J. Neurosci.,
January 15, 2003;
23(2):
493 - 502.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. K. Sastry, P. D. Lyons, M. D. Schaller, and K. Burridge
PTP-PEST controls motility through regulation of Rac1
J. Cell Sci.,
November 15, 2002;
115(22):
4305 - 4316.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Liu, W. B. Kiosses, D. M. Rose, M. Slepak, R. Salgia, J. D. Griffin, C. E. Turner, M. A. Schwartz, and M. H. Ginsberg
A Fragment of Paxillin Binds the alpha 4 Integrin Cytoplasmic Domain (Tail) and Selectively Inhibits alpha 4-Mediated Cell Migration
J. Biol. Chem.,
May 31, 2002;
277(23):
20887 - 20894.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Hagel, E. L. George, A. Kim, R. Tamimi, S. L. Opitz, C. E. Turner, A. Imamoto, and S. M. Thomas
The Adaptor Protein Paxillin Is Essential for Normal Development in the Mouse and Is a Critical Transducer of Fibronectin Signaling
Mol. Cell. Biol.,
February 1, 2002;
22(3):
901 - 915.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. A. Chellaiah, R. S. Biswas, D. Yuen, U. M. Alvarez, and K. A. Hruska
Phosphatidylinositol 3,4,5-Trisphosphate Directs Association of Src Homology 2-containing Signaling Proteins with Gelsolin
J. Biol. Chem.,
December 7, 2001;
276(50):
47434 - 47444.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Nishiya, K. Tachibana, M. Shibanuma, J.-i. Mashimo, and K. Nose
Hic-5-Reduced Cell Spreading on Fibronectin: Competitive Effects between Paxillin and Hic-5 through Interaction with Focal Adhesion Kinase
Mol. Cell. Biol.,
August 15, 2001;
21(16):
5332 - 5345.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. N. Nikolopoulos and C. E. Turner
Actopaxin, a New Focal Adhesion Protein That Binds Paxillin LD Motifs and Actin and Regulates Cell Adhesion
J. Cell Biol.,
December 27, 2000;
151(7):
1435 - 1448.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Kruger, J. R. Butler, V. Cherapanov, Q. Dong, H. Ginzberg, A. Govindarajan, S. Grinstein, K. A. Siminovitch, and G. P. Downey
Deficiency of Src Homology 2-Containing Phosphatase 1 Results in Abnormalities in Murine Neutrophil Function: Studies in Motheaten Mice
J. Immunol.,
November 15, 2000;
165(10):
5847 - 5859.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Ku and K. E. Meier
Phosphorylation of Paxillin via the ERK Mitogen-activated Protein Kinase Cascade in EL4 Thymoma Cells
J. Biol. Chem.,
April 6, 2000;
275(15):
11333 - 11340.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Shen, P. Lyons, M. Cooley, D. Davidson, A. Veillette, R. Salgia, J. D. Griffin, and M. D. Schaller
The Noncatalytic Domain of Protein-tyrosine Phosphatase-PEST Targets Paxillin for Dephosphorylation in Vivo
J. Biol. Chem.,
January 14, 2000;
275(2):
1405 - 1413.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. W. Thomas, M. A. Cooley, J. M. Broome, R. Salgia, J. D. Griffin, C. R. Lombardo, and M. D. Schaller
The Role of Focal Adhesion Kinase Binding in the Regulation of Tyrosine Phosphorylation of Paxillin
J. Biol. Chem.,
December 17, 1999;
274(51):
36684 - 36692.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Liu and M. H. Ginsberg
Paxillin Binding to a Conserved Sequence Motif in the alpha 4 Integrin Cytoplasmic Domain
J. Biol. Chem.,
July 21, 2000;
275(30):
22736 - 22742.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. D. Lyons, J. M. Dunty, E. M. Schaefer, and M. D. Schaller
Inhibition of the Catalytic Activity of Cell Adhesion Kinase beta by Protein-tyrosine Phosphatase-PEST-mediated Dephosphorylation
J. Biol. Chem.,
June 22, 2001;
276(26):
24422 - 24431.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. N. Nikolopoulos and C. E. Turner
Integrin-linked Kinase (ILK) Binding to Paxillin LD1 Motif Regulates ILK Localization to Focal Adhesions
J. Biol. Chem.,
June 22, 2001;
276(26):
23499 - 23505.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J.-F. Cote, P. L. Chung, J.-F. Theberge, M. Halle, S. Spencer, L. A. Lasky, and M. L. Tremblay
PSTPIP Is a Substrate of PTP-PEST and Serves as a Scaffold Guiding PTP-PEST Toward a Specific Dephosphorylation of WASP
J. Biol. Chem.,
January 18, 2002;
277(4):
2973 - 2986.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 1999 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|